Enter a player name to begin or load your saved progress.
The chemical formula provided for Pranlukast is C27H23N5O4.
Answer: True
Explanation: The chemical formula C27H23N5O4 accurately represents the elemental composition of a Pranlukast molecule.
The IUPAC name provided for Pranlukast is a brief identifier used mainly for marketing purposes.
Answer: False
Explanation: The IUPAC name for Pranlukast is a systematic, detailed chemical nomenclature, not a brief marketing identifier.
The molar mass of Pranlukast is stated to be 481.512 grams per mole.
Answer: True
Explanation: The molar mass of Pranlukast is precisely documented as 481.512 g/mol, a critical value for stoichiometric calculations.
The CAS Registry Number for Pranlukast is 4718.
Answer: False
Explanation: The CAS Registry Number for Pranlukast is 103177-37-3, not 4718 (which is the ChemSpider ID).
The InChI Key provided for Pranlukast is NBQKINXMPLXUET-UHFFFAOYSA-N.
Answer: True
Explanation: NBQKINXMPLXUET-UHFFFAOYSA-N is the correct InChI Key associated with Pranlukast, serving as a standardized identifier for its chemical structure.
The brand name Onon (オノン) is associated with the drug Montelukast.
Answer: False
Explanation: The brand name Onon (オノン) is associated with Pranlukast, not Montelukast.
The UNII identifier for Pranlukast is TB8Z891092.
Answer: True
Explanation: TB8Z891092 is the correct Unique Ingredient Identifier (UNII) assigned to Pranlukast by the FDA.
What is the trade name under which Pranlukast is sold?
Answer: Onon (オノン)
Explanation: Pranlukast is marketed under the trade name Onon (オノン).
What is the chemical formula for Pranlukast?
Answer: C27H23N5O4
Explanation: The chemical formula for Pranlukast is C27H23N5O4, detailing the precise atomic composition of the molecule.
What is the molar mass of Pranlukast?
Answer: Approximately 481.512 g/mol
Explanation: The molar mass of Pranlukast is precisely stated as 481.512 grams per mole (g·mol⁻¹).
Which CAS Registry Number is assigned to Pranlukast?
Answer: 103177-37-3
Explanation: The CAS Registry Number uniquely identifying Pranlukast is 103177-37-3.
Which of the following is NOT listed as a chemical identifier for Pranlukast in the source text?
Answer: FDA National Drug Code (NDC)
Explanation: While numerous identifiers like CAS Number, PubChem CID, and ChEMBL ID are provided, the FDA National Drug Code (NDC) is not listed in the source material for Pranlukast.
What is the IUPAC name for Pranlukast?
Answer: N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
Explanation: The systematic IUPAC name for Pranlukast is N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide, providing a precise description of its molecular structure.
The SMILES string provided for Pranlukast represents its:
Answer: Molecular structure
Explanation: The SMILES (Simplified Molecular Input Line Entry System) string is a notation used to represent the molecular structure of chemical compounds in a linear text format.
Which database uses the identifier ChEMBL21333 for Pranlukast?
Answer: ChEMBL
Explanation: The identifier ChEMBL21333 is specific to the ChEMBL database, which curates information on bioactive molecules.
The CompTox Chemicals Dashboard identifier for Pranlukast is provided as:
Answer: DTXSID3043782
Explanation: DTXSID3043782 is the identifier assigned to Pranlukast within the CompTox Chemicals Dashboard.
Which identifier, assigned by the FDA, is associated with Pranlukast?
Answer: UNII (Unique Ingredient Identifier)
Explanation: The UNII (Unique Ingredient Identifier), assigned by the FDA, is one of the identifiers associated with Pranlukast.
The medication known by the brand name Singulair shares a similar mechanism of action with Pranlukast.
Answer: True
Explanation: Pranlukast and Singulair (montelukast) are both classified as cysteinyl leukotriene receptor antagonists, indicating they share a similar pharmacological mechanism of action.
Pranlukast functions therapeutically by activating the cysteinyl leukotriene receptor-1 (CysLT1).
Answer: False
Explanation: Pranlukast functions therapeutically by antagonizing, not activating, the cysteinyl leukotriene receptor-1 (CysLT1). It blocks the receptor's response to leukotrienes.
Leukotrienes are chemical substances that contribute to airway relaxation.
Answer: False
Explanation: Leukotrienes are potent inflammatory mediators that contribute to airway constriction and inflammation, particularly in conditions like asthma, rather than relaxation.
Pranlukast is classified as a cysteinyl leukotriene receptor-1 antagonist.
Answer: True
Explanation: This classification accurately reflects Pranlukast's mechanism of action, where it competitively binds to and blocks the CysLT1 receptor, thereby inhibiting the effects of cysteinyl leukotrienes.
Pranlukast is primarily used to manage symptoms by increasing airway constriction during allergic reactions.
Answer: False
Explanation: Pranlukast manages symptoms by decreasing airway constriction, achieved by antagonizing the effects of leukotrienes.
Pranlukast is used to inhibit the action of leukotrienes.
Answer: True
Explanation: Pranlukast functions by inhibiting the action of leukotrienes through antagonism of their receptors.
Pranlukast functions as a leukotriene receptor agonist.
Answer: False
Explanation: Pranlukast acts as a leukotriene receptor antagonist, blocking the receptor's activation, rather than an agonist which would activate it.
Pranlukast is categorized under 'Eicosanoid activation' due to its mechanism.
Answer: False
Explanation: Pranlukast is categorized under 'Eicosanoid inhibition' because it targets leukotrienes, which are a class of eicosanoids, by inhibiting their action.
What is the principal pharmacological classification of the medication Pranlukast?
Answer: A cysteinyl leukotriene receptor-1 antagonist.
Explanation: Pranlukast is primarily classified as a cysteinyl leukotriene receptor-1 (CysLT1) antagonist, indicating its role in blocking the action of specific inflammatory mediators involved in respiratory conditions.
What is the main therapeutic function of Pranlukast?
Answer: To antagonize bronchospasm, particularly in asthma.
Explanation: The primary therapeutic function of Pranlukast is to antagonize bronchospasm, which is the constriction of the airways, a key symptom in asthma management.
How does Pranlukast achieve its therapeutic effect?
Answer: By acting as an antagonist at the cysteinyl leukotriene receptor-1 (CysLT1).
Explanation: Pranlukast achieves its therapeutic effect by acting as an antagonist at the CysLT1 receptor, thereby blocking the pro-inflammatory and bronchoconstrictive actions of leukotrienes.
According to the source, what role do leukotrienes play in conditions like asthma?
Answer: They act as inflammatory mediators causing airway constriction.
Explanation: Leukotrienes are key inflammatory mediators that contribute significantly to asthma pathophysiology by causing bronchospasm (airway constriction) and inflammation.
What does the term 'antagonist' mean in the context of Pranlukast's action on the CysLT1 receptor?
Answer: It means Pranlukast binds to the receptor but blocks its activation by other molecules.
Explanation: When Pranlukast acts as an antagonist, it binds to the CysLT1 receptor without activating it, thereby preventing endogenous ligands like leukotrienes from binding and initiating their signaling cascade.
Pranlukast's categorization under 'Eicosanoid inhibition' is relevant because:
Answer: Leukotrienes, which it inhibits, are a class of eicosanoids.
Explanation: The relevance stems from leukotrienes being a subclass of eicosanoids, and Pranlukast's mechanism involves inhibiting their action by blocking their receptors.
Pranlukast works by blocking the effects of which specific type of inflammatory mediator?
Answer: Leukotrienes
Explanation: Pranlukast functions by blocking the effects of leukotrienes, which are key inflammatory mediators involved in conditions such as asthma.
According to the provided information, Pranlukast is primarily prescribed and utilized within the North American region.
Answer: False
Explanation: The source material indicates that Pranlukast is widely used in Japan, not primarily in North America.
Pranlukast is typically administered through intravenous injection.
Answer: False
Explanation: Pranlukast is administered orally, not via intravenous injection.
Pranlukast is generally recommended as a primary, standalone treatment for asthma.
Answer: False
Explanation: Pranlukast is typically used as an adjunct therapy, meaning it complements standard asthma treatments rather than serving as the primary standalone therapy.
Pranlukast is widely prescribed in the European region.
Answer: False
Explanation: The information indicates Pranlukast is widely used in Japan, not typically in the European region.
Pranlukast is typically administered via inhalation.
Answer: False
Explanation: Pranlukast is administered orally, not through inhalation.
Pranlukast is intended to be used as a standalone therapy for managing asthma.
Answer: False
Explanation: Pranlukast is generally employed as an adjunct therapy, supplementing other standard asthma treatments, rather than as a standalone treatment.
In which country is Pranlukast commonly prescribed according to the provided information?
Answer: Japan
Explanation: The source material explicitly states that Pranlukast is widely used in Japan.
What is the standard route of administration for Pranlukast?
Answer: Oral administration
Explanation: Pranlukast is administered orally, meaning it is taken by mouth as part of its therapeutic regimen.
In asthma treatment, Pranlukast is typically used as:
Answer: An adjunct therapy alongside standard treatments.
Explanation: Pranlukast is generally administered as an adjunct therapy, meaning it supplements other established treatments for asthma, rather than being the sole or primary therapeutic agent.
The term 'adjunct therapy' implies that Pranlukast is used:
Answer: As a supplementary treatment added to other therapies.
Explanation: Adjunct therapy signifies that Pranlukast is administered in conjunction with, and to supplement, other primary treatments for a condition.
Pranlukast has an elimination half-life of approximately 12 hours.
Answer: False
Explanation: The elimination half-life of Pranlukast is approximately 1.5 hours, significantly shorter than 12 hours.
The metabolism of Pranlukast primarily takes place in the kidneys.
Answer: False
Explanation: Pranlukast undergoes metabolism primarily in the liver, not the kidneys.
The enzyme CYP3A4 plays a significant role in the metabolism of Pranlukast.
Answer: True
Explanation: CYP3A4 is a key enzyme involved in the hepatic metabolism of Pranlukast.
The elimination half-life of Pranlukast is 1.5 days.
Answer: False
Explanation: The elimination half-life of Pranlukast is approximately 1.5 hours, not 1.5 days.
The source details a pharmacokinetic study of Pranlukast hydrate dry syrup conducted specifically in adults.
Answer: False
Explanation: The referenced pharmacokinetic study of Pranlukast hydrate dry syrup was conducted in children diagnosed with allergic rhinitis and bronchial asthma, not adults.
What is the elimination half-life of Pranlukast?
Answer: Approximately 1.5 hours
Explanation: The elimination half-life of Pranlukast is approximately 1.5 hours, indicating a relatively rapid clearance from the body.
Which organ is the primary site for Pranlukast metabolism?
Answer: Liver
Explanation: The liver serves as the primary organ for the metabolic processing of Pranlukast.
Which enzyme is mainly involved in the hepatic metabolism of Pranlukast?
Answer: CYP3A4
Explanation: The enzyme CYP3A4 plays a principal role in the hepatic metabolism of Pranlukast.
A study on the population pharmacokinetics of Pranlukast hydrate dry syrup mentioned in the source was conducted in:
Answer: Children diagnosed with allergic rhinitis and bronchial asthma
Explanation: The referenced pharmacokinetic study specifically investigated Pranlukast hydrate dry syrup in pediatric populations diagnosed with allergic rhinitis and bronchial asthma.
In experimental settings, Pranlukast has been investigated for its potential to inhibit infections caused by *Mycobacterium tuberculosis*.
Answer: True
Explanation: Research has explored Pranlukast's potential efficacy in inhibiting *Mycobacterium tuberculosis* infections in experimental models.
The ATC code R03DC02 indicates that Pranlukast is an antibiotic.
Answer: False
Explanation: The ATC code R03DC02 classifies Pranlukast as a leukotriene receptor antagonist used for obstructive airway diseases, not an antibiotic.
Pranlukast is a leukotriene receptor antagonist that functions similarly to Zafirlukast.
Answer: True
Explanation: Pranlukast, Zafirlukast, and Montelukast are all leukotriene receptor antagonists that target the CysLT1 receptor and are considered to have similar efficacy.
Which medication is mentioned as having a similar mechanism of action to Pranlukast?
Answer: Montelukast
Explanation: Montelukast, marketed as Singulair, is explicitly mentioned as having a similar mechanism of action to Pranlukast.
The ATC code R03DC02 is associated with Pranlukast. What does this code primarily indicate?
Answer: Pranlukast is a leukotriene receptor antagonist for obstructive airway diseases.
Explanation: The ATC code R03DC02 specifically classifies Pranlukast as a leukotriene receptor antagonist used in the management of obstructive airway diseases within the respiratory system category.
What potential therapeutic application for Pranlukast has been explored in experimental models?
Answer: Inhibiting *Mycobacterium tuberculosis* infection
Explanation: Experimental investigations have explored Pranlukast's potential to inhibit *Mycobacterium tuberculosis* infections.
Pranlukast is considered equally effective as which other group of medications?
Answer: Other leukotriene receptor antagonists
Explanation: The source indicates that Pranlukast is considered equally effective as other medications within the same class, namely other leukotriene receptor antagonists like Montelukast and Zafirlukast.
In the ATC classification system, what does the 'R' in Pranlukast's code (R03DC02) represent?
Answer: Respiratory system
Explanation: In the ATC classification system, the 'R' prefix signifies drugs acting on the Respiratory system.